Cart
sales@molnova.com
S55746
CAS No. 1448584-12-0
S55746( BCL201 | BCL-201 | S 55746 | S-55746 | Servier-1 )
Catalog No. M11923 CAS No. 1448584-12-0
S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 67 | Get Quote |
|
| 5MG | 99 | Get Quote |
|
| 10MG | 180 | Get Quote |
|
| 25MG | 327 | Get Quote |
|
| 50MG | 520 | Get Quote |
|
| 100MG | 750 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameS55746
-
NoteResearch use only, not for human use.
-
Brief DescriptionS55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM.
-
DescriptionS55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM, 70- 400 fold selectivity over BCL-XL, on significant binding to MCL-1 and BFL-1; potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM, exhibits a much weaker activity in H146 (IC50 1.7 μM), a BCL-XL-dependent cell line; concentration-dependently disrupts the BCL-2/BAX complex in RS4;11 cells, selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner; induces cell death in a panel of non-Hodgkin lymphoma cells; inhibits xenograft growth in RS4;11 and Toledo models.Blood Cancer Phase 1 Clinical.
-
In VitroWestern Blot AnalysisCell Line:H146 and RS4;11 cell lines.Concentration:0, 0.1, 0.3 and 1 μM.Incubation Time:72 hours.Result:Potently induced RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM.
-
In VivoAnimal Model:Female SCID/beige mice implanted subcutaneously with 3×106 Toledo or RS4;11. Dosage:20, 50, 100 mg/kg.Administration:Oral gavage daily for 7 consecutive days.Result:Induced significant anti-tumor activity time- and dose-dependently.Animal Model:SCID/beige female mice with RS4;11 tumor xenografts.Dosage:25 and 100 mg/kg.Administration:Single oral gavage treatment.Result:Did not induce platelet loss in vivo at 25 and 100 mg/kg.
-
SynonymsBCL201 | BCL-201 | S 55746 | S-55746 | Servier-1
-
PathwayAngiogenesis
-
TargetBcl-2
-
RecptorBcl-2
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1448584-12-0
-
Formula Weight710.831
-
Molecular FormulaC43H42N4O6
-
Purity>98% (HPLC)
-
SolubilityDMSO : 50 mg/mL 70.34 mM; H2O : < 0.1 mg/mL
-
SMILESO=C(C1=C2CCCCN2C(C3=C(C(N4CC5=C(C=CC=C5)C[C@H]4CN6CCOCC6)=O)C=C(OCO7)C7=C3)=C1)N(C8=CC=C(O)C=C8)C9=CC=CC=C9
-
Chemical Name(S)-N-(4-hydroxyphenyl)-3-(6-(3-(morpholinomethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)benzo[d][1,3]dioxol-5-yl)-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Orobol
Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover. Orobol inhibits PI3K isoforms with IC50s of 3.46-5.27 μM for PI3K α/β/γ/K/δ. Orobol exhibits anti-skin-aging and anti-obesity effects.
-
trans-Ferulic acid
Trans-Ferulic acid causes the phosphorylation of β-catenin resulting in proteasomal degradation of β-catenin and increases the expression of pro-apoptotic factor Bax and decreases the expression of pro-survival factor survivin.trans-Ferulic acid exert both anti-proliferation and anti-migration effects in the human lung cancer cell line H1299.
-
Bcl-xL antagonist 2
Bcl-xL antagonist 2 is an effective and selective antagonist of Bcl-xL with an IC50 of 91 nM and a Ki of 65 nM. Bcl-xL antagonist 2 induces apoptosis in cancer cells and can be used in studies about chronic lymphocytic leukemia and non-Hodgkin’s lymphoma.
